Literature DB >> 3840882

Bronchodilators and diuretics in children with bronchopulmonary dysplasia.

M M Logvinoff, R J Lemen, L M Taussig, B A Lamont.   

Abstract

Pulmonary function tests (PFT) were obtained during the course of a self-controlled study of six children aged 5 to 43 months who had moderate to severe bronchopulmonary dysplasia (BPD). Changes after the administration of intravenous (IV) furosemide (2 mg/kg), inhaled isoproterenol (0.2 cc, 1:200), inhaled atropine sulfate (0.05 mg/kg), and a placebo were assessed. The study indicated the furosemide and atropine significantly (P less than 0.05) increased dynamic compliance (CL) for the group. A decrease in total pulmonary resistance (RL) and work of breathing (W) was observed after isoproterenol, although the responses were not significant (P = 0.08 and P = 0.09, respectively). It was speculated that pulmonary edema and increased vagal tone may contribute to small airway dysfunction in children who have BPD.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3840882     DOI: 10.1002/ppul.1950010406

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

Review 1.  Bronchopulmonary dysplasia: then and now.

Authors:  W H Northway
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 2.  Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.

Authors:  Audra Stewart; Luc P Brion
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

3.  Early detection of lung function abnormalities in infants with cystic fibrosis.

Authors:  R Kraemer
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

4.  Dose-response relationships and time course of the response to systemic beta adrenoreceptor agonists in infants with bronchopulmonary disease.

Authors:  R Kraemer; P Birrer; M H Schöni
Journal:  Thorax       Date:  1988-10       Impact factor: 9.139

5.  Short-time response characteristics of salbutamol in infants with broncho-pulmonary diseases.

Authors:  R Kraemer; P Birrer; F H Sennhauser; M H Schöni
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Authors:  Rishika P Sakaria; Ramasubbareddy Dhanireddy
Journal:  Front Pediatr       Date:  2022-03-09       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.